No Influence of V617F Mutation in JAK2 on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelofibrosis

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 12, 2006, Pages 1350-1351

  Ditschkowski, Markus ^a   Elmaagacli, Ahmet H ^a   Trenschel, Rudolf ^a   Steckel, Nina K ^a   Koldehoff, Michael ^a   Beelen, Dietrich W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; VALINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LETTER; MYELOFIBROSIS; MYELOID METAPLASIA; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; SURVIVAL; TREATMENT OUTCOME;

AMINO ACID SUBSTITUTION; BIOLOGICAL MARKERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JANUS KINASE 2; KAPLAN-MEIERS ESTIMATE; MUTATION, MISSENSE; MYELOFIBROSIS; MYELOID METAPLASIA; POINT MUTATION; POLYCYTHEMIA VERA; PROGNOSIS; RECURRENCE; RISK; SURVIVAL ANALYSIS; THROMBOCYTHEMIA, HEMORRHAGIC; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33845235224     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.07.010     Document Type: Letter

References (8)

1. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
2. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemica vera. Nature 434 (2005) 1144-1148
3. Jones A.V., Kreil S., and Zoi K. Widespread occurrence of JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
4. Levine R.L., Wadleigh M., and Cools J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
5. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
6. Campbell P.J., Griesshammer M., Döhner K., et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107 (2006) 2098-2100
7. Guardiola P., Anderson J.E., Bandini G., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93 (1999) 2831-2838
8. Ditschkowski M., Beelen D.W., Trenschel R., et al. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 34 (2004) 807-813